Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | Chief Commercial Officer | December 24, 2019 | December 27, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date December 24, 2019 · Filed December 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,608 |
Reported balance
After 2019-12-24 transaction · row 1
1 source rowRow 1 · 2019-12-24 · Purchase · Acquired 3,000 · Balance 8,608 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 24, 2019 Filed Dec 27, 2019 12:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 3,000 | $3.90 | $11,700.00 |
DisclosureSEC source: 0001104659-19-076289 · tm1927404-1_4.xml · nonDerivative · entry 1 Araya Arturo · CIK 0001699800 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,608 Read SEC document |
| August 28, 2018 Filed Sep 4, 2018 21:02 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001144204-18-047847 · tv501988_4.xml · derivative · entry 2 Araya Arturo · CIK 0001699800 · Director · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-08-27 F2 · derivative.exercise_date: Option shall vest and become exercisable as to 25% of the underlying shares on each of the first, second, third and fourth anniversary of the date of grant, until fully vested and exercisable on the fourth anniversary of the date of grant, provided Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date. Read SEC document |
| August 28, 2018 Filed Sep 4, 2018 21:02 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | Disposition to issuerCommon Stock | 2,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-047847 · tv501988_4.xml · nonDerivative · entry 1 Araya Arturo · CIK 0001699800 · Director · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,608 F1 · shares: Represents unvested shares of restricted common stock awarded by Issuer to Reporting Person on February 26, 2018 and March 26, 2018, forfeited pursuant to Reporting Person's August 28, 2018 employment agreement with Issuer. Read SEC document |
| March 26, 2018 Filed Mar 26, 2018 20:45 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 1,249 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-016909 · tv489424_4.xml · nonDerivative · entry 1 Araya Arturo · CIK 0001699800 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,413 F1 · shares: Shares acquired are shares of restricted stock awarded on March 26, 2018 pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan and the reporting person's election to the Governance, Nominating and Compensation Committee. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on April 26, 2018 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a member of the Governance, Nominating and Compensation Committee of the Board of Directors of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 22:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 4,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-011819 · tv487354_4.xml · nonDerivative · entry 1 Araya Arturo · CIK 0001699800 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,164 F1 · shares: Shares acquired are shares of restricted stock awarded on February 26, 2018 pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 26, 2018 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| February 26, 2017 Filed Mar 3, 2017 22:33 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 3,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-012785 · v460632_4.xml · nonDerivative · entry 1 Araya Arturo · CIK 0001699800 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,012 F1 · shares: Shares acquired are shares of restricted stock awarded on February 26, 2017 pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 26, 2017 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.